Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment options--commentary

R J Arceci1

  • 1Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA.

The British Journal of Cancer. Supplement
|September 1, 1994
PubMed
Summary

New therapeutic strategies are being explored for Langerhans cell histiocytosis (LCH) in children lacking effective treatments. This includes novel agents and advanced therapies for complex LCH cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biology of Langerhans cells and Langerhans cell histiocytosis.

International review of cytology·2006
Same author

Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.

Leukemia·2005
Same author

Clinical trials and tribulations.

Journal of pediatric hematology/oncology·2002
Same author

STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.

Oncogene·2001
Same author

Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.

Leukemia & lymphoma·2001
Same author

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.

Blood·2001

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Immunology

Background:

  • Langerhans cell histiocytosis (LCH) presents significant treatment challenges for some pediatric patients.
  • Multisystem disease, organ dysfunction, and chronic relapsing patterns complicate LCH management.
  • Long-term complications like fibrosis and central nervous system (CNS) involvement require novel therapeutic approaches.

Purpose of the Study:

  • To identify and discuss critical unmet needs in pediatric LCH treatment.
  • To review emerging therapeutic strategies for difficult-to-treat LCH cases.
  • To provide an overview of novel chemotherapeutic agents, immunosuppressive strategies, bone marrow transplantation, and gene therapy for LCH.

Main Methods:

  • Review of current clinical problem areas in pediatric LCH.
  • Exploration of novel therapeutic modalities.
  • Discussion of advanced treatment options including transplantation and gene therapy.

Main Results:

  • Identified key patient groups with LCH requiring new therapies: multisystem disease, chronic relapsing disease, pituitary involvement with diabetes insipidus, and long-term organ damage.
  • Highlighted the potential of novel chemotherapeutic agents and immunosuppressive strategies.
  • Discussed the role of bone marrow transplantation and gene therapy as advanced treatment options.

Conclusions:

  • Significant unmet needs persist in pediatric Langerhans cell histiocytosis (LCH) treatment.
  • Novel chemotherapeutic agents, immunosuppressive strategies, bone marrow transplantation, and gene therapy offer promising avenues for managing complex LCH cases.
  • Further research and clinical trials are essential to optimize outcomes for all children with LCH.

Related Experiment Videos